Roche’s MabThera Gets NICE OK Second Time Around On New Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has reversed its earlier decision on Roche’s MabThera for ANCA-associated vasculitis after the Swiss company plugged vital evidence gaps.